Nuvation Bio
Dec 12, 2019
Omega’s sixth funding round; Correvio’s drug failure; and BIMA acquisition
A leading global international investment firm, Omega Funds has announced the closure of its sixth fundraising USD 438 Million. More than decade old Life Sciences-based investment firm specialized in direct secondary transactions, Omega funds focuses in investing in Life Sciences vertical, aiming to fulfil the ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
